Amphastar Pharmaceuticals (AMPH) vs LB Pharmaceuticals (LBRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
LB Pharmaceuticals (LBRX) has outperformed Amphastar Pharmaceuticals (AMPH) over the past year, gaining 113.4% versus a loss of 1.1%. LB Pharmaceuticals is the larger company by market cap ($1.08 billion vs $1.07 billion), about 1.0 times the size. On valuation, Amphastar Pharmaceuticals trades at a lower trailing P/E (14.9x vs 334.0x for LB Pharmaceuticals).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMPH | LBRX |
|---|---|---|
| Share price | $25.25 | $33.40 |
| Market cap | $1.07B | $1.08B |
| 1-day change | -1.14% | -2.22% |
| YTD return | -4.63% | +53.46% |
| 1-year return | -1.12% | +113.37% |
| 5-year return | +33.65% | — |
| P/E ratio (TTM) | 14.94 | 334.00 |
| Forward P/E | 7.94 | — |
| EPS (TTM) | $1.69 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $29.52 | $50.16 |
| 52-week low | $16.65 | $14.32 |
| Distance from 52-week high | -14.46% | -33.41% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -10.89% | +71.56% |
| Average volume | 472.61K | 341.17K |
| Shares outstanding | 42.54M | 32.26M |
| Employees | 1,976 | 49 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LBRX has outperformed AMPH by 114.5 percentage points over the past year.
- LB Pharmaceuticals trades at a higher earnings multiple (334.0x vs 14.9x trailing P/E).
About Amphastar Pharmaceuticals
AMPH stock →Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable form of low molecular weight heparin for the prevention and treatment of deep vein thrombosis; and REXTOVY and Naloxone for opioid overdose.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,976 employees
About LB Pharmaceuticals
LBRX stock →LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees
AMPH vs LBRX FAQ
Which is bigger, Amphastar Pharmaceuticals or LB Pharmaceuticals?
LB Pharmaceuticals (LBRX) is larger, with a market capitalization of $1.08B compared with $1.07B for Amphastar Pharmaceuticals (AMPH).
Which stock has performed better over the past year, AMPH or LBRX?
LBRX returned +113.37% over the past 12 months, compared with -1.12% for AMPH (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMPH or LBRX?
AMPH has the lower trailing P/E at 14.9, versus 334.0 for LBRX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Amphastar Pharmaceuticals and LB Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.